MaxCyte, Inc. (MXCT)
NMS · Healthcare · Medical Devices
Closing price as of 2026-09-11 · Source: TEK2day Finance
Key Metrics
About MaxCyte, Inc.
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 6.8M | 7.3M | 9.7M | 7.3M |
| Gross Profit | 5.2M | 5.7M | 8.1M | 5.6M |
| Operating Income | (11.1M) | (7.7M) | (6.2M) | (10.2M) |
| Net Income | (12.4M) | (9.6M) | (4.8M) | (8.9M) |
| Diluted EPS | $-0.12 | $-0.09 | $-0.04 | $-0.08 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 44.3M | 41.3M | 38.6M | 33.0M |
| Gross Profit | 39.2M | 36.5M | 31.5M | 26.8M |
| Operating Income | (27.4M) | (48.3M) | (51.2M) | (45.3M) |
| Net Income | (23.6M) | (37.9M) | (41.1M) | (44.6M) |
| Diluted EPS | $-0.23 | $-0.37 | $-0.39 | $-0.42 |